Table 3.

Overall survival and patient characteristics of the entire patient population (n = 1106) and the diabetic patient population (n = 186)

	Entire Patient Population (n = 1106)			Diabetic Patient Population (n = 186)
Characteristic	OS (m) n	95 % CI	p	OS (m) n	95 % CI	p
Gender			<0.0001			0.087
Female	23.0 520	19.2–26.8		26.9 86	13.5–40.4
Male	14.9 586	13–16.9		14.3 100	12–16.5
Age			0.369			0.926
≤61	18.7 544	16.6–20.9		16.4 59	12.2–20.7
> 61	17.4 562	12.8–22		18.3 127	7.3–29.2
Smoking history			0.01			0.065
No	23.8 456	20.1–27.4		27.3 82	22.8–31.9
Yes	15.2 650	13.4–17		13.8 104	11.8–15.9
Histology			0.089			0.678
Other	14.2 352	11.1–17.2		14.9 60	10.3–19.6
Adenocarcinoma	20.2 754	17.4–23		16.4 126	7.5–25.4
Stage			<0.0001			0.012
II-IIIa	38.5 63	17.3–59.7		61.1 12	–
IIIb-IV	17.2 1043	14.8–19.6		15.2 174	12.8–17.6
Diabetes			0.619
Yes	18.5 186	16.2–20.7
No	16.4 920	8.3–24.5
Metformin use			0.046			0.017
No	18.3 995	15.9–20.6		13.2 75	12.0–14.5
Yes	25.6 111	13.7–37.6		25.6 111	13.7–37.6
Insulin use			0.743			0.718
No	19 1087	16.4–20.4		17.0 165	8.4–25.6
Yes	15.8 19	8.6–22.9		15.8 21	8.6–23.0
Glibenclamide use			0.703			0.473
No	18.4 1046	16.4–20.5		17.0 126	5.2–28.7
Yes	15.2 60	9.8–20.3		15.2 60	9.8–20.6
Glycemic control			<0.001			<0.0001
Improper (≥130 mg/dLa)	12.1 208	10.1–14.1		13.2 127	12–14.4
Proper (<130 mg/dLa)	19.8 887	17.2–22.3		40.5 58	11.1–69.8
Glycemic control and diabetesb			<0.001
Proper diabetic control	40.5 58	11.2–69.8
Improper diabetic control	13.2 127	11.9–14.4
Non-diabetic	18.4 920	16.2–20.8

OS Overall Survival, m Months

^a Calculated mean serum glucose ^b One patient with missing glucose values